ASCO: Risks of Whole Brain Radiotx May Outweigh Benefits
Second study suggests new immunotherapy may benefit patients with glioblastoma
May 2015 Briefing – Hematology & Oncology
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2015. This roundup includes...
ASCO: Greater Breast Tissue Removal Reduces Further Surgery
Removing extra tissue can halve the chances of requiring a second surgery in breast cancer
ASCO: Palbociclib Ups Survival in HR+ Metastatic Breast Cancer
Adding palbociclib to standard hormone therapy kept disease from progressing for nine months
ASCO: Lymph Node Sx Doesn’t Benefit All Melanoma Patients
Second study supports new immunotherapy for enhanced survival in advanced melanoma
ASCO: Rx Strategies Promising for CLL, Non-Hodgkin’s Lymphoma
Ibrutinib, obinutuzumab slow progression of CLL, non-Hodgkin's lymphoma
ASCO: MMR Deficiency Predicts Pembrolizumab Response
Findings may help doctors better choose patients to receive pembrolizumab (Keytruda)
AMA: Physicians Driving the Slowing of Health Care Costs
Physicians' spending grew more slowly over 2003 to 2013 than hospital and clinical spending
ASCO: PD-1 Immunotherapy Benefits Patients With NSCLC
Fewer side effects, longer survival for nivolumab versus docetaxel
Population-Based FIT Screening Can Reduce CRC Mortality
Large cohort study shows significant reduction among screened 50- to 69-year-olds in Taiwan
